{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:52:42Z","timestamp":1792079562336,"version":"4.4.0"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1766","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has licensed 2026-2027 formulas of the mRNA COVID-19 vaccines Comirnaty, Spikevax, and mNEXSPIKE1 and the adjuvanted protein subunit COVID-19 vaccine Nuvaxovid. The vaccines are FDA-licensed for use in adults \u226565 years old and in persons aged 6 months-64 years (Spikevax), 5-64 years (Comirnaty), or 12-64 years (mNEXSPIKE, Nuvaxovid) who are at high risk for severe COVID-19 because of an underlying condition.<\/jats:p>","DOI":"10.58347\/tml.2026.1766a","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:33:41Z","timestamp":1792078421000},"page":"169-171","source":"Crossref","is-referenced-by-count":0,"title":["2026-2027 COVID-19 Vaccination"],"prefix":"10.58347","volume":"68","member":"37151","published-online":{"date-parts":[[2026,10,26]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:33:41Z","timestamp":1792078421000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1766a"}},"subtitle":[],"editor":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,10,26]]},"references-count":0,"journal-issue":{"issue":"1766","published-online":{"date-parts":[[2026,10,26]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2026.1766a","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,26]]}}}